Skip to main content

Advertisement

SpringerLink
Log in

CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

CXCL10, a member of the CXC chemokine family, is known to mediate chemotaxis, apoptosis, angiogenesis, and cell growth. It is also reportedly involved in tumor development and can affect prognosis in several cancers. However, the precise relationship between CXCL10 and the prognosis of patients with esophageal squamous cell carcinoma (ESCC) is not fully understood.

Methods

We used ESCC tissue microarrays containing samples from 177 patients to test whether the CXCL10 expression status, determined using immunohistochemical analysis, is predictive of prognosis. We also tested whether CXCL10 expression status could serve as a clinically useful marker for evaluating the need for adjuvant chemotherapy after surgery.

Results

We found that high CXCL10 expression in clinical samples was an independent prognostic factor and was predictive of a favorable 5-year overall survival and disease-specific survival (p = 0.0102 and 0.0332, respectively). Additionally, no significant difference was detected between patients in the CXCL10-high group treated with surgery alone and those treated with surgery followed by adjuvant chemotherapy. In the CXCL10-low group, on the other hand, patients treated with surgery followed by adjuvant chemotherapy had better 5-year overall survival than those treated with surgery alone.

Conclusions

High CXCL10 expression is an independent prognostic factor and has the potential to serve as a clinically useful marker of the need for adjuvant chemotherapy after surgery in patients with advanced thoracic ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center M, et al. Global cancer statics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2002;232:225–32.

    Article  Google Scholar 

  3. Law S, Kwong D, Wong KF, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339–47.

    PubMed Central  PubMed  Google Scholar 

  4. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.

    Article  PubMed  Google Scholar 

  5. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.

    Article  CAS  PubMed  Google Scholar 

  6. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

    Article  PubMed  Google Scholar 

  7. Sanuki N, Ishikura S, Shinoda M, et al. Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. Int J Clin Oncol. 2012;17:105–11.

    Article  PubMed  Google Scholar 

  8. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer. Oncol Lett. 2011;2:583–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9:287–300.

    Article  CAS  PubMed  Google Scholar 

  10. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–63.

    Article  CAS  PubMed  Google Scholar 

  11. Ki DH, Jeung HC, Park CH, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer. 2007;121:2005–12.

    Article  CAS  PubMed  Google Scholar 

  12. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004;64:55–63.

    Article  CAS  PubMed  Google Scholar 

  13. Talbot SG, Estilo C, Maghami E, et al. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res. 2005;65:3063–71.

    CAS  PubMed  Google Scholar 

  14. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  15. Lu L, Pan K, Zheng HX, et al. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother. 2013;36:451–8.

    Article  CAS  PubMed  Google Scholar 

  16. Yoo JY, Choi HK, Choi KC, et al. Nuclear hormone receptor corepressor promotes esophageal cancer cell invasion by transcriptional repression of interferon-γ-inducible protein 10 in a casein kinase 2–dependent manner. Mol Biol Cell. 2012;23:2943–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Sobin LH, Gospodarowicz MK, Wittekind C, International Union Against Cancer. TNM classification of malignant tumours. 7th ed. Chichester: Wiley; 2010.

    Google Scholar 

  18. Sato Y, Motoyama S, Maruyama K, et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201:188–93.

    Article  PubMed  Google Scholar 

  19. Sato Y, Motoyama S, Nanjo H, et al. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy. Ann Surg Oncol. 2013;20:3044–51.

    Article  PubMed  Google Scholar 

  20. Sato Y, Marzese DM, Ohta K, et al. Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma. Epigenetics. 2013;8:1043–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.

    Article  CAS  PubMed  Google Scholar 

  22. Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep. 2010;37:3029–36.

    Article  CAS  PubMed  Google Scholar 

  23. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med. 2007;28:87–114.

    Article  CAS  PubMed  Google Scholar 

  24. Aronica SM, Raiber L, Hanzly M, et al. Antitumor/antiestrogenic effect of the chemokine interferon inducible protein 10 (IP-10) involves suppression of VEGF expression in mammary tissue. J Interferon Cytokine Res. 2009;29:83–92.

    Article  CAS  PubMed  Google Scholar 

  25. Fujita M, Zhu X, Ueda R, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells—significant roles of CXCL10. Cancer Res. 2009;69:1587–95.

    Article  CAS  PubMed  Google Scholar 

  26. Jiang XB, Lu XL, Hu P, et al. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine. 2009;27:6210–6.

    Article  CAS  PubMed  Google Scholar 

  27. Rainczuk A, Rao JR, Gathercole JL, Fairweather NJ, et al. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. Int J Cancer. 2014;1;134:530–41.

    Article  Google Scholar 

  28. Furuya M, Suyama T, Usui H, et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol. 2007;38:1676–87.

    Article  CAS  PubMed  Google Scholar 

  29. Datta D, Flaxenburg JA, Laxmanan S, et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006;66:9509–18.

    Article  CAS  PubMed  Google Scholar 

  30. Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 2007;26:4679–88.

    Article  CAS  PubMed  Google Scholar 

  31. Lo BK, Yu M, Zloty D, et al. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol. 2010;176:2435–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Maru SV, Holloway KA, Flynn G, et al. Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol. 2008;199:35–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Supported in part by JSPS KAKENHI (Grant 25870072).

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan

    Yusuke Sato MD, PhD, Satoru Motoyama MD, PhD, Akiyuki Wakita MD, PhD, Kei Yoshino MD, PhD, Tomohiko Sasaki MD, PhD, Yushi Nagaki MD, Jiajia Liu MD, PhD, Kazuhiro Imai MD, PhD, Hajime Saito MD, PhD & Yoshihiro Minamiya MD, PhD

  2. Department of Pathology, Akita University Graduate School of Medicine, Akita, Japan

    Hiroshi Nanjo MD, PhD

Authors
  1. Yusuke Sato MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Motoyama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Nanjo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akiyuki Wakita MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kei Yoshino MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomohiko Sasaki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yushi Nagaki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jiajia Liu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuhiro Imai MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hajime Saito MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshihiro Minamiya MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yusuke Sato MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sato, Y., Motoyama, S., Nanjo, H. et al. CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 23, 936–942 (2016). https://doi.org/10.1245/s10434-015-4909-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4909-1

Keywords

Search

Navigation